Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orasure Technologies ( (OSUR) ) has issued an announcement.
On February 25, 2026, OraSure reported fourth-quarter 2025 net revenue of $26.8 million, in line with expectations and above the midpoint of guidance, though down 29% year over year as total 2025 revenue fell 38% to $115.0 million, reflecting steep declines in COVID-19, risk assessment testing, and molecular services. Management highlighted improved funding stability in key segments, stronger gross margins, a solid balance sheet, and an active $40 million share repurchase program, and said the business is positioned to return to growth in 2026 as it prepares U.S. launches of a rapid molecular self-test for chlamydia and gonorrhea and the Colli-Pee at-home urine collection device for sexually transmitted infections.
The most recent analyst rating on (OSUR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.
Spark’s Take on OSUR Stock
According to Spark, TipRanks’ AI Analyst, OSUR is a Neutral.
OSUR scores low primarily due to weak financial performance (losses and challenged cash flow) and bearish technical momentum (below key moving averages with negative MACD). Offsetting factors include a strong balance sheet highlighted on the earnings call and a potentially positive FDA-related product catalyst, but these are not yet enough to outweigh current operating headwinds and negative earnings.
To see Spark’s full report on OSUR stock, click here.
More about Orasure Technologies
OraSure Technologies, Inc., based in Bethlehem, Pa., is a diagnostics company specializing in point-of-need and home diagnostic tests and sample management solutions. The company focuses on decentralizing diagnostics through products that enable at-home testing and collection, particularly in infectious diseases and sexually transmitted infections, and supports customers navigating shifting healthcare funding dynamics.
Average Trading Volume: 569,920
Technical Sentiment Signal: Sell
Current Market Cap: $202.3M
For an in-depth examination of OSUR stock, go to TipRanks’ Overview page.